Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Challenges of drug resistance in the management of pancreatic cancer

1 Oct 2010

Abstract excerpt

The current treatment of choice for metastatic pancreatic cancer involves single-agent gemcitabine or a combination of gemcitabine with capecitabine or erlotinib (a tyrosine kinase inhibitor). Only 25–30% of patients respond to this treatment and patients who do respond initially ultimately exhibit disease progression. Median survival for pancreatic cancer patients has reached a plateau due to inherent and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Treatments and Studies
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20942635
DOI: 10.1586/era.10.148

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Challenges of drug resistance in the management of pancreatic cancerPMID 20942635Read ↗

Overcoming drug resistance in pancreatic cancer.Semantic proximity Read ↗

The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overviewSemantic proximity Read ↗

The Landscape of Pancreatic Cancer Therapeutic Resistance MechanismsSemantic proximity Read ↗

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53Semantic proximity Read ↗

Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.Semantic proximity Read ↗

MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potentialSemantic proximity Read ↗

Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Semantic proximity Read ↗

Review. Molecular background of chemoresistance in pancreatic cancer.Semantic proximity Read ↗

Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotypeSemantic proximity Read ↗

Noncoding RNAs in drug-resistant pancreatic cancer: A reviewSemantic proximity Read ↗

Emerging role of microRNAs to tackle drug resistance in pancreatic cancerSemantic proximity Read ↗

Emerging drugs in the treatment of pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.